Mesa Laboratories (MLAB) Q4 2024 earnings summary

Executive summary

• Achieved 6% revenue growth in 4Q24 year-over-year, with sequential growth of 10.2% from 3Q24; full-year revenues declined 1.3% due to core organic headwinds in BPD and CG, partially offset by GKE acquisition.

• Recorded a $274.5M non-cash impairment charge, resulting in a GAAP operating loss of $271.3M for 4Q24 and $272.1M for FY24.

• Non-GAAP adjusted operating income excluding unusual items rose 26.3% in 4Q24 and 0.7% for FY24, reflecting cost controls and GKE synergies.

• Strategic milestones included GKE China acquisition, expanded credit facility, partial repurchase of 2025 Convertible Notes, and CG division restructuring.

Financial highlights

• 4Q24 revenues: $58.9M (+6% YoY); FY24 revenues: $216.2M (-1.3% YoY).

• 4Q24 net loss: $254.6M (GAAP), or $(47.20) per diluted share; FY24 net loss: $254.2M, or $(47.20) per diluted share.

• 4Q24 non-GAAP AOI excluding unusual items: $14.9M (+26.3% YoY); FY24: $50.5M (+0.7% YoY).

• Gross profit for 4Q24: $36.6M; for FY24: $133.3M.

• Cash and equivalents at FY24-end: $28.2M; total assets: $444.8M; stockholders’ equity: $145.4M.

Outlook and guidance

• Focus on expanding in Asia Pacific and leveraging GKE synergies.

• Monitoring biopharmaceutical capital spending recovery; cautious on sustained rebound.

• Preparing for potential impacts from new FDA regulations on lab developed tests in CG.

• Continued emphasis on organic growth and operational agility amid macroeconomic and regulatory uncertainty.